PCVX catalysts
Catalysts and events linked to PCVX, newest first.
PCVX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering 2026-10-07 · Mixed | equity supply dilution and convertible arbitrage delta hedging | Vaxcyte announced pricing for $1B gross proceeds offerings: 7.4M shares at $64.00 and $500M convertible notes. | Not recorded |
| Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% Convertibles 2026-10-07 · Mixed | equity dilution and convertible arbitrage delta hedging flow | Pricing of 7.4M shares at $64.00 and $500M in 1.50% convertible notes | Not recorded |
| Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes 2026-10-07 · Mixed | equity dilution and convertible arbitrage short delta hedging | Vaxcyte priced 7.4M shares at $64.00 and $500M in 1.50% 2032 convertible notes. | Not recorded |
| Vaxcyte prices $1 billion concurrent common stock and convertible note offerings 2026-10-07 · Mixed | equity dilution and convertible arbitrage hedging pressure | Vaxcyte announced pricing of concurrent common stock and $500M convertible note offerings. | Not recorded |
| Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible Notes 2026-10-07 · Mixed | equity float expansion at fixed discount to market | Vaxcyte priced 7.4 million common shares at $64.00 and $500M in 1.50% convertible notes. | Not recorded |
| Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt Offerings 2026-10-07 · Mixed | equity dilution and convertible note supply overhang balanced by extended cash runway | Vaxcyte announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds at $64.00 per share. | Not recorded |
| Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering 2026-10-07 · Down | equity dilution and convertible note arbitrage delta selling | Vaxcyte announced pricing of 7.4 million shares at $64.00 and $500 million of 1.50% convertible senior notes. | Not recorded |
| Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes 2026-10-07 · Mixed | equity dilution and convertible arbitrage short-selling pressure | Priced $1B offering including 7.4M shares at $64.00 and $500M convertible debt. | Not recorded |
Do these developments change your position?
Review PCVX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-07Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes OfferingPCVX-2.90%
- 2026-10-07Vaxcyte prices $1.0B concurrent offering of common stock and convertible notesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 NotesPCVX-2.90%
- 2026-10-07Vaxcyte prices $1 billion concurrent common stock and convertible note offeringsPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1 Billion Concurrent Common Stock and Convertible Debt OfferingsPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes OfferingPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible NotesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1 Billion Concurrent Public Offering of Stock and Convertible NotesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible OfferingPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Capital Raise via Common Equity and 1.50% ConvertiblesPCVX-2.90%
- 2026-10-07Vaxcyte Prices $1B Concurrent Public Offering of Equity and Convertible NotesPCVX-2.90%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.